Newsroom | 37094 results

RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the second quarter ended June 30, 2025. In connection with a likely sale of the Company’s Products & Healthcare Services segment, the results herein, unless otherwise noted, reflect the Company’s continuing operations which primarily represent what was previously the Patient Direct segment and certain functional operations. “We are in the final stages of our robust process for the divest...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August of an aggregate of 12,731 restricted stock units (RSUs) of the company’s common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant d...

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conferences: The 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2025. The RBCCM Medical Supplies & Devices Virtual Symposium virtually on August 18, 2025, from 10:00am – 11:00am ET. The Piper Sandler MedTech and Di...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. ET on Monday, August 11, 2025. The Company’s common stock will c...

DUBLIN--(BUSINESS WIRE)--The "Europe Defibrillator Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Europe defibrillator market achieved USD 3.87 billion in 2024 and is expected to expand to USD 7.23 billion by 2033, growing at a CAGR of 7.2% from 2025 to 2033. The market is growing due to the growing prevalence of cardiovascular disease, raising awareness of emergency cardiac care, and technology advan...

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties, inc...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”)...

明尼阿波利斯--(BUSINESS WIRE)--(美国商业资讯)-- Edison®组织摧毁术系统及新型组织摧毁术治疗平台的研发企业HistoSonics今日宣布，由一批全球知名的私人和公共投资者组成的联盟将以管理层主导的方式收购其多数股权，投资方包括K5 Global、Bezos Expeditions、Wellington Management以及其他新老投资者。此次交易对HistoSonics的估值约为22.5亿美元，将助力公司加速Edison系统在新临床适应症及全球市场的增长。 HistoSonics将继续由总裁兼首席执行官Mike Blue及其管理团队领导。交易完成后，Blue先生还将担任董事会主席一职。 Blue先生表示：“作为一家公司，我们始终专注于速度、规模，以及为患者提供比现有方案更优选择的迫切使命。这批新合作伙伴支持那些定义品类、变革整个行业的企业。他们的支持将为我们注入动力，加速发展势头，拓展至新的临床适应症，惠及全球更多急需我们突破性疗法的患者。” HistoSonics计划在初始聚焦的肝肿瘤之外，将业务扩展至肾、胰腺和前列腺肿瘤适应症，其长期愿景是让组织摧毁...

明尼亞波里斯--(BUSINESS WIRE)--(美國商業資訊)-- Edison®組織摧毀術系統及新型組織摧毀術治療平台的研發企業HistoSonics今日宣布，由一批全球知名的私人和公共投資人組成的聯盟將以管理層主導的方式收購其多數股權，投資方包括K5 Global、Bezos Expeditions、Wellington Management以及其他新投資人和現有投資人。此次交易對HistoSonics的估值約為22.5億美元，將協助公司加快Edison系統在新臨床適應症及全球市場的成長。 HistoSonics將繼續由總裁兼執行長Mike Blue及其管理團隊領導。交易完成後，Blue先生還將擔任董事長一職。 Blue先生表示：「身為一家公司，我們始終專注於速度、規模，以及為病患提供比現有方案更優選擇的迫切使命。這批新合作夥伴支援那些定義品類、變革整個產業的企業。他們的支援將為我們注入動力，加大發展動力，擴大至新的臨床適應症，嘉惠全球更多亟需我們突破性療法的病患。」 HistoSonics計畫在初始聚焦的肝腫瘤之外，將業務擴充至腎、胰腺和攝護腺腫瘤適應症，其長期願景是讓組織摧...

ミネアポリス--(BUSINESS WIRE)--（ビジネスワイヤ） -- Edison®（エジソン）ヒストトリプシー・システムおよび新規ヒストトリプシー治療プラットフォームの開発企業であるヒストソニックスは、K5グローバル、ベゾス・エクスペディションズ、ウエリントン・マネージメント、および新規・既存の投資家を含むグローバルに認知された民間・公的投資家のシンジケートによる経営陣主導の過半数株式取得を発表しました。取引によりヒストソニックスは約22億5000万ドルの評価を受け、新規臨床適応とグローバル市場におけるエジソン・システムの成長加速が可能になります。 ヒストソニックスは、社長兼最高経営責任者（CEO）のマイク・ブルーと経営陣が引き続き率いていきます。ブルーは取引完了後、取締役会会長を兼務します。 「当社が企業として徹底して重視してきたのは、スピードと規模、そして今あるどの選択肢よりも優れた治療法を患者にいち早く提供することです」とブルーは述べています。「新たなパートナーとなるこのグループは、業界全体を変革するカテゴリー定義企業を支援してきました。支援により企業としての水準が向上...